Lidakang Secures RMB 110 Million Series A Funding Led by Shenzhen Capital Group and Hetang Venture Capital

Investment Circle (WeChat ID: pedaily2012) reported on January 31 that “LDK” completed a RMB 110 million Series A financing round, which was jointly invested by SCGC and Hetang Venture Capital.

Beijing LDK Technology Co., Ltd., established in 1998, has evolved through nearly two decades of continuous innovation and development into a high-tech enterprise specializing in artificial joints, integrating research and development, manufacturing, sales, and services. Its main products include the titanium alloy microporous hip joint system, the high-flexion posterior-stabilized knee joint system, the modular bone tumor joint system, and a series of 3D-printed products.

LDK’s independently developed “bone tumor joint” products—modular tumor joints and customized tumor joints—have preserved limbs for thousands of bone tumor patients annually, earning high recognition from orthopedic experts and scholars. Meanwhile, the continuous launch of new products in the Jixiang™ Generation II JXII™ series, along with hip and knee product lines and instruments for revision arthroplasty, has injected new vitality into the application of LDK products in the field of hip and knee joint replacement and revision surgery. The introduction of the Ta-coated biological femoral stem has filled the gap in the domestic orthopedic field regarding the application of new materials with surface-active antibacterial biological coatings.

Mr. Yi Hongxiang, Partner at SCGC Health Industry Fund, stated, “We are pleased to invest in LDK. Artificial joints in the orthopedic industry represent a key sector within the health industry that SCGC has been continuously focusing on, and LDK will be our first strategic entry into the orthopedics segment. Against the broader trends of population aging, import substitution, and healthcare cost containment under medical insurance schemes, LDK is poised to build stronger brand influence among domestic joint manufacturers in China. This potential is underpinned by its twenty years of technological expertise in artificial joint products, the implementation of a professional management system over the past two years, as well as its passionate and proactive team and robust product R&D capabilities.”

This article is an original piece by the investment community, authored by yorke. Original source: https://pe.pedaily.cn/201901/440132.shtml